Protective Effect of Amifostine Against Toxicity of Paclitaxel and Carboplatin in Non-small Cell Lung Cancer: A Single Center Randomized Study
- 1 January 2003
- journal article
- clinical trial
- Published by Springer Nature in Medical Oncology
- Vol. 20 (3) , 237-246
- https://doi.org/10.1385/mo:20:3:237
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- The potential role of amifostine in the treatment of non small cell lung cancerLung Cancer, 2000
- Amifostine plus cisplatin plus vinorelbine in the treatment of advanced non small cell lung cancer: a multicenter phase II studyLung Cancer, 2000
- Impairment of heart rate variability during paclitaxel therapyCancer, 2000
- Paclitaxel and Docetaxel Combinations in Non-Small Cell Lung CancerChest, 2000
- Amifostine: A selective cytoprotective agent of normal tissues from chemo-radiotherapy induced toxicity (Review).Oncology Reports, 1999
- Acute myocardial infarction following paclitaxel administration for ovarian carcinomaClinical Oncology, 1997
- Amifostine (Ethyol®): Pharmacokinetic and Pharmacodynamic Effects in vivoEuropean Journal Of Cancer, 1996
- Paclitaxel-induced myocardial damage detected by electron microscopyThe Lancet, 1994
- Zur Ototoxizität des Zytostatikums Carboplatin bei Patienten mit Kopf-Hals-Tumoren*Laryngo-Rhino-Otologie, 1992
- Carboplatin is ototoxicCancer Chemotherapy and Pharmacology, 1990